<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6335">
  <stage>Registered</stage>
  <submitdate>26/10/2016</submitdate>
  <approvaldate>26/10/2016</approvaldate>
  <nctid>NCT02951182</nctid>
  <trial_identification>
    <studytitle>A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis</studytitle>
    <scientifictitle>A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-000454-36</secondaryid>
    <secondaryid>VX15-440-101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tezacaftor
Treatment: drugs - Ivacaftor
Treatment: drugs - VX-440
Treatment: drugs - Matched Placebos

Experimental: Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC) - VX-440 200 milligram (mg) administered every 12 hours (q12h). TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.
Morning Dose: VX-440 + TEZ/IVA
Evening Dose: VX-440 + IVA

Placebo Comparator: Heterozygous F508del/MF 4-week Cohort A: Triple Placebo - Placebos matched to VX-440, TEZ/IVA, and IVA.

Experimental: Heterozygous F508del/MF 4-week Cohort B TC-High - To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
The dosage of VX-440 may be adjusted based on data from Cohort A.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA

Experimental: Heterozygous F508del/MF 4-week Cohort B:TC-Low - To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebo matched to VX-440
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA

Placebo Comparator: Heterozygous F508del/MF 4- week Cohort B: Triple Placebo - To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebos matched to VX-440, TEZ, and IVA.

Experimental: Homozygous F508del/F508del 4-week Cohort: TC- High - To be initiated after the Cohort A blinded review, if supported by safety and PK data.
The dosage of VX-440 may be adjusted based on data from Cohort A.
Placebo matched to morning TEZ/IVA.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA
The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.

Active Comparator: Homozygous F508del/F508del 4-week Cohort: TEZ/IVA - To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebos matched to VX-440, evening TEZ, and morning IVA.
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.
Morning Dose: TEZ/IVA
Evening Dose: IVA
The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.

Experimental: Heterozygous F508del/MF 12-week Cohort: TC-High - To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA

Experimental: Heterozygous F508del/MF 12-week Cohort: TC-Low - To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to VX-440
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA

Experimental: Heterozygous F508del/MF 12-week Cohort: Dual IVA - To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to TEZ.
Morning Dose: VX-440 + IVA
Evening Dose: VX-440 + IVA

Experimental: Heterozygous F508del/MF 12-week Cohort: Dual TEZ - To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to IVA
Morning Dose: VX-440 + TEZ
Evening Dose: VX-440 + TEZ
VX-440 administered in combination with TEZ q12h and placebo matched IVA.

Placebo Comparator: Heterozygous F508del/MF 12-week Cohort: Triple Placebo - To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
Placebos matched to VX-440, TEZ, and IVA.


Treatment: drugs: Tezacaftor


Treatment: drugs: Ivacaftor


Treatment: drugs: VX-440


Treatment: drugs: Matched Placebos


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</outcome>
      <timepoint>from baseline up to 16 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)</outcome>
      <timepoint>from baseline up to 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in sweat chloride concentrations</outcome>
      <timepoint>from baseline up to 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relative change in ppFEV1</outcome>
      <timepoint>from baseline up to 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of pulmonary exacerbations</outcome>
      <timepoint>through Week 12 (12-week cohort only)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first pulmonary exacerbation</outcome>
      <timepoint>through Week 12 (12-week cohort only)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in body mass index (BMI)</outcome>
      <timepoint>from baseline at Week 12 (12-week cohort only)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in BMI z-score</outcome>
      <timepoint>from baseline at Week 12 (12-week cohort only)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in weight</outcome>
      <timepoint>from baseline at Week 12 (12-week cohort only)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score</outcome>
      <timepoint>from baseline up to 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed concentration (Cmax) of VX-440, TEZ, M1-TEZ, IVA, and M1-IVA (µg/mL)</outcome>
      <timepoint>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-440, TEZ, M1-TEZ, IVA, and M1-IVA (µg.h/mL)</outcome>
      <timepoint>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Observed pre-dose concentration (Ctrough) of VX-440, TEZ, M1-TEZ, IVA, and M1-IVA (µg/mL)</outcome>
      <timepoint>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Willing and able to comply with scheduled visits, treatment plan, study restrictions,
             laboratory tests, contraceptive guidelines, and other study procedures.

          -  To prevent pregnancy, female participants of childbearing potential and their male
             partners will be required to use pre-specified, highly effective methods of
             non-hormonal contraception. Male participants with female partners of childbearing
             potential will be required to use a condom.

          -  Body weight =35 kg.

          -  Sweat chloride value =60 mmol/L from test results obtained during screening.

          -  Subjects must have an eligible CFTR genotype:

               -  Heterozygous for F508del and a minimal function (MF) mutation known or predicted
                  not to be responsive to TEZ and/or IVA.

               -  Homozygous for F508del

          -  Subjects must have an FEV1 =40% and =90% of predicted normal for age, sex, and height
             at the Screening Visit

          -  Stable CF disease as judged by the investigator.

          -  Willing to remain on a stable CF medication regimen through the planned end of
             treatment or, if applicable, the Safety Follow up Visit.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             subject.

          -  History of cirrhosis with portal hypertension.

          -  Risk factors for Torsade de Pointes

          -  History of hemolysis.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.

          -  Clinically significant abnormal laboratory values at screening

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy for pulmonary disease within 28 days before the first dose of study drug.

          -  Lung infection with organisms associated with a more rapid decline in pulmonary status

          -  An acute illness not related to CF within 14 days before the first dose of study drug

          -  A standard digital ECG demonstrating QTc &gt;450 msec at screening.

          -  History of solid organ or hematological transplantation.

          -  History or evidence of cataract or lens opacity determined to be clinically
             significant by the ophthalmologist or optometrist based on the ophthalmologic
             examination during the Screening Period.

          -  History of alcohol or drug abuse in the past year, including but not limited to,
             cannabis, cocaine, and opiates, as deemed by the investigator.

          -  Ongoing or prior participation in an investigational drug study, with certain
             exceptions. (e.g., ongoing participation in NCT02565914)

          -  Use of commercially available CFTR modulator (e.g., Kalydeco, Orkambi) within 14 days
             before screening (applies only to the Heterozygous F508del/MF cohorts; does not apply
             to the Homozygous F508del/F508del Cohort).

          -  Pregnant or nursing females: Females of childbearing potential must have a negative
             pregnancy test at screening and Day 1.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>74</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Prince Charles Hospital - Chermside</hospital>
    <hospital>John Hunter Hospital &amp; Hunter Medical Research Institute - New Lambton Heights</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Chermside</postcode>
    <postcode> - New Lambton Heights</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koeln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Seville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vertex Pharmaceuticals Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group,
      multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and
      triple combination with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with
      cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane
      conductance regulator (CFTR) gene (F508del/F508del), or who are heterozygous for the F508del
      mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA
      therapy (F508del/MF).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02951182</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>